United Therapeutics Corporation - Common Stock (UTHR)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Jul 7, 2026Investment Snapshot
- Trading 82% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- Strong ROE of 21.1% with 39.2% net margin
- Revenue growing at 11% annually
United Therapeutics Corporation - Common Stock (UTHR) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $23.3 billion . Key value metrics: P/E ratio 18.7, P/B ratio 3.96, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
United Therapeutics Corporation - Common Stock — Fundamental Analysis Summary
United Therapeutics Corporation - Common Stock (UTHR) is currently trading 82% above its Graham Number of $302.94, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 18.7x.
On financial health, UTHR shows a moderate Piotroski F-Score of 6/9, and strong return on equity of 21.1% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.11.
StockPik's composite Value Score for UTHR is 82/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
UTHR reports a high gross margin of 86.9% (sector average: 39.4%) and a strong operating margin of 46.0%.
UTHR shows revenue growing at 11% year-over-year, with earnings growing at 12%.